J Travel Med. 2022 Jan 4:taab199. doi: 10.1093/jtm/taab199. Online ahead of print.
ABSTRACT
BACKGROUND: Monitoring the characteristics and associated factors for death among pregnant and postpartum women with COVID-19 is necessary. We investigated the clinical characteristics and risk factors associated with maternal deaths in a nationwide cohort of Brazil.
METHODS: This was a population-based cohort of all pregnant and postpartum women hospitalised with COVID-19 notified to the Sistema de Informação de Vigilância Epidemiológica da Gripe of Brazil (SIVEP-Gripe), from February 2020 to September 2021. The primary outcome was time to in-hospital death, with risks factors analysed with univariable and multivariable Cox proportional hazards regression models.
RESULTS: Cumulative observation time was 248 821 person-days from hospital admission to the end of follow-up for 15 105 individuals. There were 1858 deaths (12.3%) for a maternal mortality rate of 7.5 (95% CI 7.1-7.8) per 1000 patients-days. The cumulative mortality increased over time. Black/Brown ethnicity had a higher risk of death than women self-identifying as White. Women in the North, Northeast, Central-West and Southeast regions had higher risk of death than women in the South region. The characteristics independently associated with death were a postpartum status on admission (adjusted HR 1.4 [95%CI 1.2-1.6]), pre-existing clinical conditions (adjusted HRs 1.2 [95%CI 1.1-1.3] for one and 1.3 [95%CI 1.1-1.5] for two comorbidities), hypoxemia on admission (adjusted HR 1.2 [95%CI 1.1-1.4]) and requiring non-invasive (adjusted HR 2.6 [95%CI 2.1-3.3]) or invasive ventilatory support (adjusted HR 7.1 [95%CI 5.6-9.2]).
CONCLUSION: In Brazil, the in-hospital maternal mortality rate due to COVID-19 is high and the risk of death increases with the length of hospitalisation. Socio-demographic and biological factors are associated with an increased risk of maternal death. The presence of respiratory signs and symptoms should be considered as an early markers of disease severity and an adequate management is necessary. Our findings reinforce the need for vaccination of pregnant and postpartum women against COVID-19.
PMID:34983057 | DOI:10.1093/jtm/taab199
